TY - JOUR
T1 - Critical evaluation of regulatory T cells in autoimmunity
T2 - Are the most potent regulatory specificities being ignored?
AU - Vandenbark, Arthur A.
AU - Offner, Halina
PY - 2008/9
Y1 - 2008/9
N2 - The identification of CD4+ CD25+ Foxp3+ regulatory T (Treg) cells as natural regulators of immunity in the periphery and tissues has stimulated tremendous interest in developing therapeutic strategies for autoimmune diseases. In this review, the site of origin, antigen specificity, homing markers and cytokine profiles of Treg cells were evaluated in autoimmune colitis and type 1 diabetes, two examples in which Treg cells were effective as therapy. These studies were compared with studies of Treg cells in experimental autoimmune encephalomyelitis and multiple sclerosis, where successful therapy has not yet been achieved. Antigen-specific Treg cells appear to have more potent activity than polyclonal Treg cells and therefore hold more promise as therapeutic agents. However, Treg cells specific for the pathogenic T effector cells themselves have largely been overlooked and deserve consideration in future studies.
AB - The identification of CD4+ CD25+ Foxp3+ regulatory T (Treg) cells as natural regulators of immunity in the periphery and tissues has stimulated tremendous interest in developing therapeutic strategies for autoimmune diseases. In this review, the site of origin, antigen specificity, homing markers and cytokine profiles of Treg cells were evaluated in autoimmune colitis and type 1 diabetes, two examples in which Treg cells were effective as therapy. These studies were compared with studies of Treg cells in experimental autoimmune encephalomyelitis and multiple sclerosis, where successful therapy has not yet been achieved. Antigen-specific Treg cells appear to have more potent activity than polyclonal Treg cells and therefore hold more promise as therapeutic agents. However, Treg cells specific for the pathogenic T effector cells themselves have largely been overlooked and deserve consideration in future studies.
KW - Experimental autoimmune encephalomyelitis
KW - Experimental colitis
KW - Foxp3
KW - Immune therapy
KW - Multiple sclerosis
KW - Regulatory T cells
KW - Type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=49249133433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49249133433&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2567.2008.02900.x
DO - 10.1111/j.1365-2567.2008.02900.x
M3 - Review article
C2 - 18798915
AN - SCOPUS:49249133433
SN - 0019-2805
VL - 125
SP - 1
EP - 13
JO - Immunology
JF - Immunology
IS - 1
ER -